Vericel Corporation

VCEL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Revenue $63.9M $54.4M $51.2M $28.8M $19.0K $21.0K $18.0K $89.0K
Cost of Revenue $30.4M $28.3M $26.5M $17.3M $4.0K $6.0K $4.0K $34.0K
Gross Profit $33.6M $26.1M $24.7M $11.5M $15.0K $15.0K $14.0K $55.0K
Gross Margin 52.5% 47.9% 48.3% 39.9% 78.9% 71.4% 77.8% 61.8%
Operating Expenses
Research & Development $12.9M $15.3M $18.9M $21.3M $15.1M $26.0M $21.3M $12.7M
SG&A Expense $35.6M $27.4M $22.5M $13.8M $5.9M $7.8M $7.7M $5.2M
Operating Income $-15.0M $-19.2M $-16.7M $-23.5M $-21.0M $-33.8M $-29.0M $-17.8M
Operating Margin -23.4% -35.4% -32.6% -81.7% -110,336.8% -160,761.9% -161,333.3% -20,004.5%
Interest Expense $92.0K $15.0K $9.0K $6.0K $11.0K $12.0K $10.0K $40.0K
Pretax Income $-17.3M $-19.6M $-16.3M $-19.9M $-15.6M $-29.5M $-19.7M $-14.6M
Income Tax Expense $0 $0 $0 $0 $0 — — —
Net Income $-17.3M $-19.6M $-16.3M $-19.9M $-15.6M $-29.5M $-19.7M $-14.6M
Net Margin -27.0% -36.0% -31.9% -69.2% -82,221.1% -140,352.4% -109,266.7% -16,357.3%
EPS (Basic) $-0.52 $-1.18 $-0.97 $-2.23 $-6.95 $-16.25 $-10.18 $-0.59
EPS (Diluted) $-0.52 $-1.18 $-0.97 $-2.23 $-6.95 $-16.25 $-10.18 $-0.59
Shares Outstanding (Basic) 35.9M 31.6M 23.8M 23.8M 4.7M 2.2M 38.6M 24.7M
Shares Outstanding (Diluted) 35.9M 31.6M 23.8M 23.8M 4.7M 2.2M 38.6M 24.7M
Dividends Per Share — — — — — — — —
← Newer Page 2 of 3 Older →